Ipsc-derived human liver organoids: novel platform for determination of DE novo and therapeutic actions of extracellular vesicles in aald
Active Grant Awarded
- Award ID
- R21AA032579
- Recipient
-
Research Institute At Nationwide Children's Hospital UEI EYMJXLN2MFB4
- Awarding agency
-
National Institute on Alcohol Abuse and Alcoholism
National Institutes of Health, Department of Health and Human Services
- Obligated
- $414,750
Award facts
- Assistance listing
- 93.273 Alcohol Research Programs
- Completion date 10% complete
- Place of performance
- Columbus, OH 43205, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through the National Institute on Alcohol Abuse and Alcoholism, awarded Research Institute At Nationwide Children's Hospital $414,750 on September 11, 2026, under the Alcohol Research Programs (CFDA 93.273), Grant R21AA032579. The award funds exploratory and development studies of extracellular vesicles (EVs) in ethanol-treated three-dimensional multicellular human liver organoids (HLOs) derived from iPSCs. The work seeks to improve understanding of EV production and action in alcohol-associated liver disease and to identify new therapeutic mechanisms or candidates. Aim 1 is to identify pathways of ethanol-regulated hepatocyte EV production and action. Preliminary data show that HLOs comprise hepatocytes, cholangiocytes, endothelial cells, hepatic stellate cells, and macrophages, and that ethanol exposure produces steatosis, cell death, oxidative stress, and altered expression of genes related to lipid and ethanol metabolism, inflammation, and fibrosis. The period of performance runs from the September 11, 2026 award date to an ultimate completion date of August 31, 2028. Place of performance is Columbus, Ohio 43205. The program supports research across biomedical, genetic, psychological, environmental, health services, prevention, and treatment disciplines related to alcoholism and alcohol-related problems.
Description
- Abstract
- Alcohol-associated liver disease (AALD) is a main cause of chronic liver diseases globally as well as cirrhosis- related deaths in the USA. Our broad long-term objective to is gain improved understanding of the mechanisms of AALD and to develop new therapeutics because current treatment options are insufficient. A promising lead to address these gaps comes from the study of extracellular vesicles (EVS) which are important mediators of intercellular signaling and which have the potential to deliver therapeutic molecular cargos or agents in a broad variety of disease settings. Our overall objective is to improve our understanding of EV production and action in AALD and to leverage this information to identify new therapeutic mechanisms or candidates. We will undertake exploratory and development studies of EVS in ethanol-treated 3-dimesional multicellular human liver organoids (HLO). Our preliminary data show that hlos comprise hepatocytes, cholangiocytes, endothelial cells, hepatic stellate cells, and macrophages and that exposure of hlos to ethanol results in steatosis, cell death, oxidative stress, and altered expression of genes related to lipid and ethanol metabolism, inflammation, and fibrosis. We postulate that these responses will be broadly attenuated by EVS from normal hepatocytes because our preliminary data show that these EVS are suppressive for various ethanol effects in hepatocyte cultures. However such cultures lack the broad responses and therapeutic targets offered by multicellular hlos. Our central hypothesis is that the HLO system is a novel platform for understanding hepatocyte EV production and action as well as for determining therapeutic interventions and mechanisms. The specific aims to test this hypothesis are: aim 1: to identify pathways of ethanol-regulated hepatocyte EV production and action in hlos using a highly innovative CD63 EV labeling system to enable (I) hepatocyte exosomes to be tracked within hlos after ethanol exposure ("evtrack); and (II) their specific isolation for evaluation of their RNA and protein cargo; and aim 2: to determine mechanisms of hepatocyte EV therapy in ethanol-treated hlos which will (I) assess alterations to evtrack and (II) employ transcriptomics and proteomic analysis of HLO in conjunction with 5'-UTR gene reporter activity and gene expression manipulations to identify mirs in EV cargo from human hepatocyte cell lines or primary human hepatocytes that are therapeutic for AALD-like features in ethanolic injury in hlos. In this manner we will identify EV molecular components that of are human origin which are novel targets for key pathways related to human AALD. The rationale is that current methods of treating AALD are inadequate and our approaches are cutting-edge and innovative solutions for tracking EVS and determining EV actions in a fully human system. The expected outcome will be improved understanding of hepatocyte EV tracking and targeting in the context of ethanolic hepatic injury as well as identification of novel EV payload components that offer new leads for AALD therapy. The positive impact will be to improve the health of the many AALD patients in the USA and globally who currently have no treatment options.
Quick answers
Who received award R21AA032579?
R21AA032579 was awarded to Research Institute At Nationwide Children's Hospital by National Institute on Alcohol Abuse and Alcoholism (National Institutes of Health) on September 11, 2026.
How much is award R21AA032579 worth?
$414,750 has been obligated on R21AA032579.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award